Building a biopharmaceutical company committed to...

1/6/2003


Click here to start


Table of Contents

Building a biopharmaceutical company committed to...

Safe Harbor Statement

Amylin Pharmaceuticals, Inc. Uniquely Positioned to Build a Franchise in Metabolic Diseases

2002 Achievements

Corporate Strategy

Corporate Strategy

Corporate Strategy

SYMLIN™ (pramlintide acetate) Potential Complementary Therapy to Insulin

SYMLIN™ (pramlintide acetate) Unique Profile in Type 1 and Type 2 Diabetes

SYMLIN™ Regulatory Status

SYMLIN™ Market Opportunity United States

SYMLIN™ Market Opportunity United States

SYMLIN™ Commercial Plans United States

AC2993 (exenatide) Potential Treatment for Type 2 Diabetes

AC2993 Market Opportunity United States

AC2993 28-Day Profile in Type 2 Diabetes Potent Glucose-Lowering with No Weight Gain

AC2993 Global Collaboration with Eli Lilly and Company

AC2993 Program Update

AC2993 12-Week Profile in Type 2 Diabetes Open-label Data Show Progressive Reductions in HbA1c

AC2993 LAR Goal: Sustained-Release Treatment for Type 2 Diabetes

Corporate Strategy

Cardiovascular Disease Building on Our Strengths

Obesity Building on Our Strengths

Amylin Product Pipeline Summary

Management Experience and Expertise

Financial Overview

Milestones

Amylin Pharmaceuticals, Inc. Uniquely Positioned to Build a Franchise in Metabolic Diseases

Author: Jerry Goen